Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

This study has been completed.

Study NCT00081861 Information provided by M.D. Anderson Cancer Center

First Received: April 23, 2004 Last Updated: July 17, 2009 History of Changes

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Single Group Assignment
Condition:	Lymphoma
Interventions:	Drug: Avastin Drug: Rituximab

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: April 2004 through November 2006. All participants recruited at U.T. M.D. Anderson Cancer Center.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Avastin + Rituximab	No text entered.

Participant Flow: Overall Study

	Avastin + Rituximab
STARTED	13
COMPLETED	13^[1]
NOT COMPLETED	0

[1]	2 participants received first treatment dose but were not eligible for response due to toxicity.

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Avastin + Rituximab	No text entered.

Baseline Measures

	Avastin + Rituximab
Number of Participants [units: participants]	13
Age [units: years] Median ( Full Range )	67 ( 34 to 79 )
Gender [units: participants]
Female	6
Male	7
Region of Enrollment [units: Participants]
United States	13

Outcome Measures

1. Primary:

Number of Participants With Response (Complete Response or Progressive Disease) [ After 8 weeks of therapy (4 doses of Avastin and 8 doses of Rituximab), ]

Show Outcome Measure 1